Common Contracts
5 similar Collateral Agreement contracts by Egalet Corp, Quotient LTD, Merrimack Pharmaceuticals Inc
QUOTIENT LIMITED, ALBA BIOSCIENCE LIMITED, QBD (QS IP) LIMITED, QUOTIENT BIODIAGNOSTICS, INC., QUOTIENT SUISSE SA, QUOTIENT IBERIA, S.L.U.,Collateral Agreement • February 22nd, 2023 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of February 16, 2023, by and among QUOTIENT HOLDINGS FINANCE COMPANY LIMITED, an exempted company incorporated under the laws of the Cayman Islands (the “Issuer”), QUOTIENT HOLDINGS MERGER COMPANY LIMITED, a company incorporated under the laws of Jersey (“MergerCo”), QUOTIENT LIMITED, a public limited liability no par value company formed under the laws of Jersey with an address at 28 Esplanade, St. Helier, JE2 3QA, Jersey, Channel Islands (“Quotient”), ALBA BIOSCIENCE LIMITED, a limited company formed under the law of Scotland (“Alba”), QBD (QS IP) Limited, a private limited liability company formed under the laws of Jersey (“QBD”), QUOTIENT BIODIAGNOSTICS, INC., a corporation formed under the law of Delaware (“Biodiagnostics”), QUOTIENT SUISSE SA, a société anonyme (joint stock company) formed under the law of Switzerla
COLLATERAL AGREEMENT DATED AS OF MARCH 20, 2019 AMONGCollateral Agreement • March 20th, 2019 • Egalet Corp • Pharmaceutical preparations • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of March 20, 2019, by and among EGALET CORPORATION, a Delaware corporation with an address at 600 Lee Road, Suite 100, Wayne, Pennsylvania 19087 (the “Borrower”), the SUBSIDIARY PARTIES (as defined below) from time to time party hereto, CANTOR FITZGERALD SECURITIES, in its capacity as administrative agent for the Lenders (in such capacity, the “Agent”) and in its capacity as collateral agent for the Secured Parties (as defined below) (in such capacity, the “Collateral Agent”).
COLLATERAL AGREEMENT DATED AS OF OCTOBER 14, 2016 AMONG QUOTIENT LIMITED, as Issuer, ALBA BIOSCIENCE LIMITED, QBD (QS IP) LIMITED, QUOTIENT BIOCAMPUS LIMITED, QUOTIENT BIODIAGNOSTICS, INC., QUOTIENT SUISSE SA, THE SUBSIDIARY PARTIES FROM TIME TO TIME...Collateral Agreement • October 14th, 2016 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of October 14, 2016, by and among QUOTIENT LIMITED, a public limited liability no par value company formed under the laws of Jersey with an address at Elizabeth House, 9 Castle Street, St. Helier, JE2 3RT Jersey, Channel Islands (the “Issuer”), ALBA BIOSCIENCE LIMITED, a limited company formed under the law of Scotland (“Alba”), QBD (QS IP) Limited, a public limited liability no par value company formed under the laws of Jersey (“QBD”), QUOTIENT BIOCAMPUS LIMITED, a limited company formed under the law of Scotland (“Biocampus”), QUOTIENT BIODIAGNOSTICS, INC., a corporation formed under the law of Delaware (“Biodiagnostics”), QUOTIENT SUISSE SA, a société anonyme (joint stock company) formed under the law of Switzerland (“Suisse”), any other SUBSIDIARY PARTIES (as defined below) from time to time party hereto, U.S. BANK NA
COLLATERAL AGREEMENT DATED AS OF AUGUST 31, 2016 AMONGCollateral Agreement • September 1st, 2016 • Egalet Corp • Pharmaceutical preparations • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of August 31, 2016, by and among EGALET CORPORATION, a Delaware corporation with an address at 600 Lee Road, Suite 100, Wayne, Pennsylvania 19087 (the “Issuer”), EGALET US INC., a Delaware corporation (“Egalet US”), EGALET LIMITED, a private limited company formed under the law of England and Wales (“Egalet UK”), the other SUBSIDIARY PARTIES (as defined below) from time to time party hereto, U.S. BANK NATIONAL ASSOCIATION, in its capacity as Trustee (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”), and U.S. BANK NATIONAL ASSOCIATION, in its capacity as collateral agent for the Secured Parties (as defined below) (and its successors under the Indenture, in such capacity, the “Collateral Agent”).
COLLATERAL AGREEMENT DATED AS OF DECEMBER 22, 2015 AMONG MERRIMACK PHARMACEUTICALS, INC., as Issuer, THE SUBSIDIARY PARTIES FROM TIME TO TIME PARTY HERETO as Trustee, and as Collateral AgentCollateral Agreement • December 22nd, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of December 22, 2015, by and among MERRIMACK PHARMACEUTICALS, INC., a Delaware corporation with an address at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139, (the “Issuer”), the SUBSIDIARY PARTIES (as defined below) from time to time party hereto, U.S. BANK NATIONAL ASSOCIATION, in its capacity as Trustee (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”), and U.S. BANK NATIONAL ASSOCIATION, in its capacity as collateral agent for the Secured Parties (as defined below) (and its successors under the Indenture, in such capacity, the “Collateral Agent”).
